uk.finance.yahoo.com
Cure8 news brief
Why This Matters
ENTYVIO (vedolizumab) is a commonly used biologic for moderate-to-severe ulcerative colitis and Crohn’s disease — updates about its formulations, approvals, and market growth can affect access and availability.
News about the SC option and geographic expansion may matter to patients considering route of administration and clinicians managing biologic choices.
Who Should Pay Attention
Adult patients with moderate-to-severe ulcerative colitis or Crohn’s disease, clinicians who prescribe biologics, patients on or considering vedolizumab/other biologics, and health policy or payer stakeholders.
Study Snapshot
Story typeBusiness news
Evidence typeMarket or Business News
Source depthFull source text
What To Know
This article is a paid press release summarizing a DelveInsight market report about ENTYVIO (vedolizumab). It highlights that vedolizumab is approved for IV and subcutaneous use for ulcerative colitis and Crohn’s disease, notes global exposure and growing sales, and discusses market drivers like rising IBD prevalence and new formulations.
ENTYVIO’s mechanism as an alpha4beta7 integrin antagonist and typical IV dosing schedule are described. The piece focuses on market size, forecasted sales, competitor landscape, and commercial factors rather than new clinical data or patient-care guidance.
Because this is a commercial market report press release, it’s useful for understanding availability, formulation options (IV and SC), and broad trends, but it does not provide clinical recommendations or new efficacy/safety findings.
Keep In Mind
This is a paid press release summarizing a market research report; it emphasizes commercial forecasts and product descriptions rather than new clinical trial results. It does not change clinical practice or provide new safety/effectiveness data. For treatment decisions, consult clinical guidelines and your care team.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationuk.finance.yahoo.com
Indexed viaBing News
Source typeBusiness news
PublishedApr 15, 2025, 2:31 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Takeda's ENTYVIO Continues Growth Trajectory in Ulcerative Colitis and Crohn's Disease
This article reports on ENTYVIO (vedolizumab), a biologic used in Crohn's disease and ulcerative colitis, highlighting broader availability of a subcutaneous option and ongoing market growth—topics that can affect drug...
Eli Lilly’s Omvoh for Crohn’s disease approved by FDA
A new FDA approval means an additional biologic treatment option for adults with moderate to severe Crohn's disease. This may affect treatment choices and insurance coverage discussions for people with IBD.
FDA Approves Lilly's Omvoh For Crohn's Disease Treatment - Nasdaq
A newly FDA-approved biologic (Omvoh/mirikizumab) gives adults with moderately to severely active Crohn's disease another targeted treatment option. It's the same IL-23–targeting drug already approved for ulcerative...